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Studies of Transketolase Abnormality in
Alzheimer's Disease
Kwan-Fu Rex Sheu, PhD; Donald D. Clarke, PhD; Young-Tai Kim, PhD;
John P. Blass, MD, PhD; Bradford J. Harding; Joseph DeCicco

• The partially purified transketolase
from each of eight well-nourished patients
with Alzheimer's disease contained significantly less heat-stable component with a
significantly longer half-life of heat inactivation than that from eight controls.
lmmunochemical studies utilizing anti·
bodies to the purified human liver transke·
tolase did not distinguish between red
blood cell transketolases of patients with
Alzheimer's disease and those of controls. However, three brains from patients
with Alzheimer's disease that were deficient in transketolase activity lacked a
69-kilodalton form on immunoblots. Subtle str\Jctural abnormalities of transketolase appear to occur in a high proportion
of patients with Alzheimer's disease.
(Arch Neuro/1988;45:841·845)

Data in a previous article 1 indicate a
45% to 50% deficiency in the
activity of the enzyme transketolase
(TK; EC 2.2.1.1) in the brains of
patients with Alzheimer's disease, a
statistically significant 15% reduction in its activity in cultured Alzheimer skin fibroblasts grown in the
presence of excess thiamine, and a
subtle but statistically significant
diminution of its saturation with the
cofactor thiamine pyrophosphate
(TPP) in red blood cells from wellnourished patients with Alzheimer's
disease. An inherent abnormality in
TK has been described in WernickeKorsakoff syndrome2•4; in that condition, an apparently inherited decrease
in the ability of TK to bind its cofactor, TPP, predisposes patients to
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develop Wernicke-Korsakoff syndrome on a diet marginal in thiamine.
In both Alzheimer's disease and Wernicke-Korsakoff syndrome, neuropathologic studies have shown
marked loss of the cholinergic cells of
the nucleus basalis. 5•6 In both syndromes, there is a marked loss of
working (short-term) memory. 7•8 In
Alzheimer's disease, there are also
profound deficits in reference (longerterm) memory as well.
We have therefore examined the
properties of Alzheimer TK in greater
detail using kinetic analysis of the
heat inactivation of the red blood cell
enzyme and immunochemical techniques with antibodies raised against
the purified human liver enzyme.
These studies are described in detail
below. Preliminary results have been
presented previously.9
MATERIALS AND METHODS
Tissues

Red blood cells were obtained from
patients with Alzheimer's disease and cognitively intact controls as described previously.1 Brains from patients who had died
of Alzheimer's disease or of other disorders without impairment of cognition were
stored at -80°C. Frontal cortex from the
frontal pole to 3 em behind the frontal pole
was homogenized as described below.
Diagnoses were confirmed neuropathologically.
Sample Preparations

Transketolase was partially purified
from red blood cells by a modification of
the procedure of Schellenberg et al. 10 These
preparations were routinely performed in
parallel using paired samples from one
patient with Alzheimer's disease and one
control. Fifteen milliliters of the washed,1
frozen red blood cells were thawed at room
temperature and mixed vigorously in
capped 50-mL centrifuge tubes with 22 mL
of cold distilled water containing 2 mmol/
L phenylmethylsulfonyl fluoride. Toluene
(60% of the volume of the original packed
cells) was added and the suspension mixed
again vigorously. After being stirred for 20
minutes, the sample was centrifuged at
2000 g for 20 minutes. The toluene upper
layer and the white fluffy material at the

interface were aspirated. The lower hemolysate fraction (30 mL) was dialyzed
against 4 L of 10 mmol/L TRIS (hydrochloric acid) (pH 8.3) at 4°C overnight. For the
heat inactivation studies, an aliquot of 1
mL of the dialyzed hemolysate was applied
to a column (1.5 X 20 em) of diethylaminoethyl (DEAE)-cellulose (coarse grade; BioRad Laboratories, Richmond, Calif) that
had been thoroughly pre-equilibrated with
10 mmol/L TRIS (hydrochloric acid) (pH
8.3). Meticulous equilibration of the column was necessary for reproducible
results. The column was eluted with 10
mmol/L TRIS (hydrochloric acid) (pH 8.3)
at room temperature at a flow rate of 0.5
mL/min and fractions of 2 mL were collected. The TK activity was eluted with the
void volume,l0 while more than 95% of the
protein (mostly hemoglobin) was retained.
For immunochemical analysis, 3 to 5 mL of
the dialyzed hemolysate was chromatographed through a DEAE-cellulose column
of 2.5 X 45 em as described above. The
fractions that contained TK activity were
pooled and the solution was concentrated,
using an ultrafiltration cell with a YM-10
filter (Amicon Corp, Lexington, Mass), to 3
to 5 mL with TK activity of 100 to 200
mU/mL. These column fractions and concentrated material were stored at 4oc; no
significant loss of enzyme activity was
observed after one week. Studies requiring
activity measurements (heat inactivation
and activity-antibody titration) were regularly performed within two days.
For brain, samples of 300 to 400 mg were
homogenized under a biohazard hood in 3
mL of 20 mmol/L 3-(N-morpholino)propanesulfonic acid (pH adjusted to 7.2 with
TRIS), 2 mmol/L dithioreitol, 0.1 mmol/L
TPP, and 0.01 mmol/L leupeptin hemisulfate. Octyl phenoxy polyethoxyethanol
(Triton-X 100) and Lubrol PX were then
added in final concentrations of 1 mg/mL
each. These homogenates were frozen at
-80°C for three to four hours, thawed in a
30°C water bath, and centrifuged at 9000 g
for 15 minutes in a microfuge (Eppendorf).
The supernatants, which contained all the
TK activities, were subjected to immunochemical analysis as described below.
Enzyme Activity Measurements

The activity of TK was assayed as
described by Blass et al, 11 except that the
coupling enzym"E!s glycerol phosphate dehydrogenase and triosephosphate isomerase
(Sigma Chemical Co, St Louis) were
increased to 1 U/mL. One unit of TK
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activity was defined as the amount of
enzyme that catalyzed the formation of 1
,u.mol of nicotinamide adenine dinucleotide
per minute using this assay system. The
protein concentration was determined
according to Lowry et al, 12 with bovine
serum albumin as the standard.
Heat Inactivation Studies

A portion of the peak fractions or of the
pooled fractions containing TK activity
eluted from the DEAE-cellulose column
was transferred to a capped tube and incubated in a refrigerated circulator water
bath, which was maintained at exactly
61.5°C. Aliquots were withdrawn at various times for measurement of residual TK
activity. The incubation regularly lasted
for up to 90 minutes, at which time more
than 90% of the initial activity was lost.
The enzyme activities were assayed at ten
different time points.
The heat inactivation curves, when analyzed by first-order kinetics for a single
component, showed much larger variances
"than were consistent with the errors in the
measurements. A much better fit was
obtained for a model with two independent
components as described by the following
equation:
V/Vo = ae-k 1t + (1 - a)e-k21
in which Vo and Vt are initial activity and
residual activity at time t, respectively; k1
and k2 are the first-order rate constants
for the inactivation of the two kinetically
different components having proportions
of a and (1- a), respectively; and the halflives of these two components are ln(2/k1)
and In (21k2 ). Preliminary estimates of a,
k., and k2 were obtained by plotting log
(V/Vo) vs t and estimating the fit visually.
The sum of the squares of the errors (SSE)
was minimized by evaluating the partial
derivatives of SSE with respect to a, k.,
and k2, and using a Taylor series expansion
of the error function to obtain improved
estimates of a, k 11 and k2, according to
Wentworth. 13 The process was iterated
until the values of the constants did not
change by greater than one part in
100 000.
lmmunochemlcal Studies

Preparation of Antigen and Antibodies.Transketolase was purified from human
liver to specific activities of 6 to 8 U/mg of
protein. Sodium dodecyl sulfate (SDS)polyacrylamide
electrophoretic
gels
showed one protein species of 69 000 daltons. Details of the enzyme purification
and characterization will be presented
elsewhere (K.F.R.S., J.D., 0. Young, unpublished findings, 1986). Polyclonal antibodies against these highly purified TK
preparations were raised in a New Zealand
white rabbit according to the protocol
described previously. 14 The IgG fractions in
the preimmune serum and the pooled
serum samples after the first and second
boosts were prepared by ammonium sulfate precipitation and DEAE-cellulose
chromatography, 14 and finally made up in
20 mmol/L sodium phosphate (pH 7.0) in a
protein concentration of 20 mg/mL. All the
842

Arch Neuroi-Vol 45, Aug 1988

immunochemical assays described below
were performed with these IgG preparations.
Immunoblots.-Brain extracts or red
blood cell preparations were resolved on
SDS-polyacrylamide electrophoretic gels
(8%) as described by Weber and Osborn.15
The proteins were transferred electrophoretically to nitrocellulose membranes. 16•17
Transketolase on these nitrocellulose blots
was identified using the anti-TK (1:200
dilution) and horseradish peroxidase conjugated goat-antirabbit IgG second antibodies as detailed previously, 16 except that
the antibody incubations were performed
in 25 g/ L bovine serum albumin in 10
mmol/L sodium phosphate (pH 7.2) and
150 mmol/L sodium chloride, and the incubation time was extended to two hours.
Preimmune lgG did not bind to the blot
under these conditions.
Activity-Antibody Titrations.-Aliquots of
brain extract (100 to 200 ,u.L) or partially
purified red blood cell TK (concentrates of
DEAE-cellulose column eluents, 100 to 200
,u.L) were incubated with various amounts
of anti-TK IgG and preimmune IgG. Total
volume of the added IgG was 10 J.Ll (0.2 mg
of protein). Incubations were performed at
4°C overnight, then centrifuged at 9000 g
for 15 minutes in a microfuge (Eppendoi'f).
The residual TK activities in the supernatants were determined. More than 90% of
the TK activities in both Alzheimer and
control samples were recovered in incubations with the preimmune IgG alone. Six or
seven incubations were regularly performed for each sample, and residual TK
activities ranged from 100% to <20% of
the initial value. The amount of anti-TK
required to give 50% activity inhibition
(ICso) was estimated as a measure of the
TK enzyme in the sample.
Enzyme-Linked lmmunosorbent Assay
(ELISA).-Serial dilutions of the purified
hepatic TK or red blood cell TK preparations were made in 100 mmol/L sodium
bicarbonate (pH 9.6). Aliquots of 200 J.LL
were coated in the wells of polyvinylchloride microtiter plates. These wells were
then incubated with anti-TK (1: 1000 dilution) and alkaline phosphatase-conjugated
goat-antirabbit lgG second antibodies
(1 :3000 dilution; Bio-Rad Laboratories) as
detailed previously. 14 The bound alkaline
phosphatase was assayed with p-nitrophenyl phosphate in a diethanolamine buffer
(Bio-Rad Laboratories), stopped with 0.5
mol/L sodium hydroxide, and quantitated
on a microplate reader (Bio-tek EL308 EIA
reader).
RESULTS

To test for a structural abnormality
of Alzheimer TK, the heat stability of
the red blood cell enzyme from
patients with Alzheimer's disease was
compared with that from age- and
sex-matched controls (Table 1). The
yield of TK through the DEAE-cellulose chromatography step was relatively high (>85% ), suggesting that
no significant components were discarded. Fitting the heat-inactivation

curves with a model of two independent components gave a consistently
closer fit than did a one-component
system, consistent with other evidence of structural heterogeneity in
red blood cell TK. 3•15•16 Comparable
heat-inactivation curves were obtained in the presence and absence of
exogenous TPP, indicating that the
heterogeneity was not likely to be due
to variable saturation with that cofactor. The Alzheimer TK contained
more of the heat-labile (80% vs 60%;
P < .01) and less of the heat-stable
(20% vs 40%; P < .02) component
than did TK from controls (Table 1).
Furthermore, the half-life of the heatstable component was shorter for the
controls (20 minutes for controls vs 40
minutes for patients with Alzheimer's
disease; P < .01). Each of the eight
patients with Alzheimer's disease had
>70% heat-labile TK and <30% heatstable TK, while only one of the controls had this pattern.
Immunochemical studies were done
to further compare the structures of
Alzheimer and control TK. The polyclonal antibody to the highly purified
human liver TK completely inactivated the enzyme activity in red blood
cell (Fig 1, right) and brain (Fig 2),
indicating that all enzymatically
active forms of TK in these tissues
were recognized by this antibody.
Immunoblots showed that this antibody recognized the human liver TK
polypeptide of 69 kilodaltons (kd) (Fig
3, lane 1). A species of the same size
was also detected in red blood cells
(Fig 3) and in brain (Fig 4).
Immunochemical studies with this
polyclonal antibody did not distinguish between the Alzheimer and control red blood cell TKs. Affinity for
antibody appeared similar for Alzheimer and control TKs on ELISA
binding curves (Fig 1, left) and on
antibody-activity titrations (Fig 1,
right). Immunoblotting analysis indicated that both Alzheimer and control
· red blood cells had one antibody-binding species of 69 kd, a size similar to
that of the human liver TK antigen
(Fig 3). Furthermore, the stain intensities of red blood cell TKs from
patients and controls also appeared
similar (Fig 3).
Results of the previous study
showed reduced TK activity in brains
of patients with Alzheimer's disease. 1
In the present study (Table 2), three of
five brains from patients with Alzheimer's disease examined had TK
activities greater than 2 SDs below
control means. The TK activity in
these deficient brains was 1.75 + 0.34
mU/mg of protein (mean+ SEM),
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Table 1.- Heat Inactivation of Red Blood Cell Transketolase From Patients With Alzheimer's Disease•
Patients

Controls
Heat-Stable
Component

Heat-Labile
Component
Age,
y / Sex

Half-life,
min

I

48 / F

II

o/o

Age,
y/ Sex

Half-life,
min

o/o

Half-life,
min

%

16.5

31.3

83 / F

2.4

80.3

20.5

19.7

45.6

38.7

54.4

68 / F

3.6

78.0

33.7

22.0

3.2

68.7

16.0

31.3

76/M

4.6

80.0

52.0

20.0

59/F

2.7

53.5

15.0

46.6

59 / M

3.1

72.9

22.8

27.1

v

64 / M

3.3

88.8

35.2

11.1

74 / M

4.6

95.0

70.3

5.0

VI

60 / M

2.8

55.9

10.4

44.1

61 / F

2.3

91.4

22.4

8 .6

VII

50 / M

4.9

60.4

14. 1

39.6

56 / M

4.3

76.1

48.5

23.9

VIII

59 / F

5.4

56.9

21.6

43. 1

59 / M

9.5

79.2

61 .0

20.8

.. .

4.0 ± 0 .5

62.3 ± 4.7

20.9 ± 3.7

37.7 ± 4.7

...

81 .6 ± 2.7t

41 .4 ± 6.8*

%

Half·llfe,
min

5.0

68.5

61 / M

4.7

Ill

61 / F

IV

Mean ± SEM

Heat-Stable
Component

Heat-Labile
Component

4.3

±

0.8

18.4

±

2.7t

• Roman numerals designate paired samples of one patient and one control, performed in parallel.

tP < .01 vs controls (Student's two-tailed t test).

*P < .02 vs controls (Student's two-tailed t test).
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Fig 1. -lmmunoassays for red blood cell transketolase (TK) from patients with Alzheimer's
disease and controls. Left, Enzyme-linked immunosorbent assay for TK. Serial dilutions of liver TK
antigen (exes) and red blood cell TK from patients with Alzheimer's disease (solid circles and
solid squares) and controls (open circles and open squares) were coated onto wells of microtiter
plate. Bound TK was determined with specific antibodies and alkaline phosphatase-conjugated
second antibodies. Control incubations with preimmune lgG gave absorbances (410 nm) of
<0.05 under similar conditions. Right, Antibody-inactivation titration for TK. Red blood cell
preparations were incubated with preimmune lgG with various amounts of specific antibodies
(lgG). Residual enzyme activities in supernatants were determined after overnight incubation.
Open symbols (circles, triangles, and squares) were TK preparations from normal controls. Solid
symbols (circles, triangles, and squares) were TK from patients with Alzheimer's disease. Amount
of antitransketolase required to inhibit 50% of enzyme activity in normal controls was 97 4 + 134
,.,.g (mean + SO) of antitransketolase per unit of TK and in patients with Alzheimer's disease,
960 + 72 ,.,.g of antitransketolase per unit of TK.

while the activity in normal controls
was 8.25 + 0.68 mU/ mg of protein
(n = 4).

On immunoblots of the SDS-gels,
two antibody-binding species were
observed in normal control brains
(Fig 4). The smaller species was indistinguishable in size from the red blood
cell TK (70 kd), while the larger species was 72 kd. The 70-kd species was
almost absent in brains from patients
with Alzheimer's disease (lanes 4, 5,
and 10, Fig 4) that were deficient in
Arch Neuroi -Vol 45, Aug 1988
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TK activity (brains from patients 1, 2,
and 5 in Table 2), while the larger
72-kd species appeared to be normal
in these TK-deficient brains. The
SDS-gel protein profiles of these
brains were also apparently similar to
those from control brains (data not
shown).
The TKs in brains from controls
and patients with Alzheimer's disease
were further compared by antibodyactivity titrations (Fig 2 and Table 2).
The amount of antibody that gave rise

Fig 2. -Antibody-activity titration of transketolase in frontal cortex from patients with
Alzheimer's disease and controls. Activity
titrations were performed as in Fig 1, right.
Brains were as in Table 1. All open symbols
represent control brains; all solid symbols,
brains from patients with Alzheimer's disease;
and solid triangles, circles, and diamonds,
brains from patients 1, 2, and 5 (Table 2),
respectively.

to inactivation of 50% enzyme activity
(IC5o[anti-TK]) was used as a measure
of antigen-antibody binding. When
calculated per milligram of brain protein, the results reflect the amount of
antibody binding. In four of the five
brains from patients with Alzheimer's disease, including the three
brains deficient in overall TK activity,
the IC50 (anti-TK) per milligram of
protein level was more than 2 SDs
below the control mean (Table 2).
Thus, antibody-activity titrations
demonstrated an abnormality in TK
of brains from patients with Alzheimer's disease not evident in the partially purified red blood cell enzyme. In
the three brains from patients with
Alzheimer's disease with low activity
under saturating substrate conditions, the IC50 (anti-TK) per milligram
of protein level fell in a manner parallel to the fall in enzyme activity. This
result is consistent with the immuno-
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Fig 3.-lmmunoblots for transketolase (TK) in red blood cells from
patients with Alzheimer's disease and controls. Transketolase was
enriched from red blood cells by diethylaminoethyl cellulose column
chromatography. Proteins in these preparations were resolved on
sodium dodecyl sulfate-polyacrylamide electrophoretic gels and transferred to nitrocellulose membranes. Transketolase on blots was identified with specific antibodies and peroxidase-conjugated second antibodies as described in "Materials and Methods." Lane 1 contains liver
TK antigen (50 ng of protein); lanes 2 through 4, TK preparations from
normal controls (5 mU each); lanes 5 through 7, TK preparations from
patients with Alzheimer's disease (5 mU each); lane 8, normal control
TK as in lane 2 plus liver TK antigen; and lane 9, Alzheimer TK as in
lane 5 plus liver TK antigen.

Fig 4.-lmmunoblots for transketolase (TK) in frontal cortex from
patients with Alzheimer's disease and controls. lmmunoblots were
obtained as in Fig 3. Lane 1 contains TK partially purified from red blood
cells (3 mU of enzyme); lanes 2, 3, 8, and 9, control brains (80 J.Lg
protein each); lanes 4, 5, and 10, TK-deficient brains from patients with
Alzheimer's disease (from patients 1, 2, and 5, Table 2) (80 #lg of
protein each); lane 6, control brain as in lane 2 plus red blood cell TK;
and lane 7, brain from patient with Alzheimer's disease as in lane 4 plus
red blood cell TK.

Table 2.-Transketolase (TK) in Frontal Cortex From Patients With Alzheimer's Disease
Micrograms of Anti·TK Needed to
Inhibit 50% of TK Activity
Age,y/ Sex
Controls
1
2
3
4
Mean ±. SEM
Patients
1
2
3
4
5
Mean± SEM

80/F
77 / M
81 / M
58 / F

Postmortem
Delay, h
21
6
4
20

...

...

81 I F
77 / F
67 / F
72 / M
91 / F

<33
5
<24
3
13

...

. ..

TK Activity,
mU/ mg Protein

Per Milligram of
Brain Protein

TK Activity

8.14
7.54
7. 11
10.19
8.25 ± 0.68

6.70
5.68
5.20
6.55
6.03 ± 0.36

780
705
730
655
718 ± 26

1.65.
1.48.
10.78
5.80
2.13.
4.37 ± 1.79

2.35.
2.05•
7.05
4.38.
2.4o·
3.65 ± 0.94

1385t
1305t
770
750
925t
1027 ± 134

Per Unit of

• Less than 2 SDs of mean of controls.
tMore than 2 SDs of mean of controls.

blotting result (Fig 4), in which the
antibody binding for the 69-kd species
was greatly diminished. When the IC50
(anti-TK) is calculated per unit of
enzyme activity, the results reflect the
specific catalytic efficiency of the
enzyme protein antigen. The TK-deficient brains from patients with Alzheimer's disease had higher IC50 (antiTK) per unit of TK activity (ie, lower
activity per unit of antigen protein)
than other brains with normal TK
844
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activity (Table 2). This result suggests
that the TK protein in these deficient
brains from patients with Alzheimer's disease may be catalytically less
effective.
There was no consistent evidence in
studies of red blood cells or brains
that TK activity varied significantly
with age over the ranges studied.
Combined with the observation of
abnormal heat-inactivation (Table 1),
these results suggest that TK in a

substantial proportion of patients
with Alzheimer's disease may be
structurally abnormal.
COMMENT

The frequency of detection of
abnormalities in an enzyme protein
obviously depends on the nature and
sensitivity of the test(s) employed.
The kinetics of heat inactivation
reflect the structural stability of proteins. This test has been widely

Transketolase in Alzheimer's Disease-Sheu et al

employed as a relatively sensitive
probe for abnormal proteins. Immunochemical tests assess the binding of
antibody(s) to a particular antigen;
their ability to detect subtle changes
depends on whether or not the
changes affect the particular epitope(s) recognized by the antibody(s).
The heat inactivation study described
above demonstrated an abnormality
of red blood cell TK in each of the
eight patients with Alzheimer's disease studied. The abnormality appears to be subtle: it did not alter the
binding of the polyclonal antibody (in
ELISAs or antibody-activity titrations), the apparent size of the crossreacting material on SDS-gels, or the
total TK activity measured under saturation concentrations of substrates
and cofactors. 1 As noted elsewhere,
the abnormalities in red blood cell TK
do not appear to relate to dietary
thiamine deficiency. 1•18•19 These data
indicate that the TK protein is structurally different in patients with Alzheimer's disease than in controls, at
least in red blood cells. Whether or
not there is difference in amino acid
sequence is not yet known.
The 69-kd form ofTK that appeared
to be subtly abnormal in Alzheimer
red blood cells also appeared to be
present in reduced amounts in three
of the five brains examined from
patients with Alzheimer's disease, as
evidenced by activity measurements,
immunoblots, and antibody-activity
ti trations. Heat-inactivation studies
of brain TK were not done because of
technical factors. Potential artifacts
such as nonspecific aggregation and

proteolysis interfere with the interpretation of heat inactivation studies
on crude preparations. Methods are
not yet available to purify TK substantially from brain in yields high
enough to allow the assumption that
all critical components are present in
proportions similar to those in the
whole tissue. As noted in the in troduction, alterations in TK have been
found in another neurologic syndrome, the Wernicke-Korsakoff syndrome. 2-4 These syndromes differ clinically and pathologically, although
both are associated with cognitive
deficits and loss of cholinergic cells of
the nucleus basalis.5·8 Previous studies
of a second TPP-dependent enzyme
known to be deficient in brains from
patients with Alzheimer's disease,
namely, the pyruvate dehydrogenase
complex, have provided no evidence
for a structural abnormality. 20 Analogous studies of a third TPP-dependent
enzyme, the 2-ketoglutarate dehydrogenase complex/ have not yet been
completed. In rats with thiamine deficiency induced with pyrithiamine,
treatment with thiamine reversed the
acute behavioral changes and restored
the activity of 2-oxoacid dehydrogenase complexes to normal. 21 Activity
of brain TK remained depressed, suggesting that TK is more associated
with permanent "Korsakoff-like"
manifestations of experimental thiamine deficiency.
The molecular basis for the abnormality in Alzheimer TK is unknown.
Transketolase in normal red blood
cells has been reported to be heterogeneous in isoelectric point, 3·22 chro-

matographic behavior/3 and heat stability (Table 1). In the studies
described above, a polyclonal antibody
to the highly purified liver TK completely inactivated TK in red blood
cells and brain, indicating significant
structural homology of the enzyme in
those tissues. Immunoblots revealed a
69-kd species in red blood cells, while
brain also contained a larger 71-kd
species, which might prove to be a
precursor. Further studies are needed
to elucidate the structural relationships among the different forms of
TK and to determine whether the
abnormalities in Alzheimer TK are
due to abnormal post-translational or
post-transcriptional events, or reflect
changes in the gene(s) coding for
TK(s).
The pathophysiologic significance
of the abnormalities in TK are not
known. A subtle abnormality in this
protein might render it less stable in
the particular intracellular environment of (certain) brain cells compared
with red blood cells (eg, concentrations of specific ions and metabolites
and presence of specific proteases).
The reductions in TK in brains from
patients with Alzheimer's disease
may prove to reflect or to contribute
to the loss of brain cells enriched in
this enzyme protein, or both.
These studies were supported in part by grants
from the Will Rogers Institute and the Winifred
Masterson Burke Relief Foundation, both in
White Plains, NY, and the National Institutes of
Health (AG 03853).
Diagnoses of Alzheimer's disease and other
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Carole Petito, MD, Department of Pathology,
Cornell University Medical Center, New York.
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